CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | 1.8% | – | 99.3% | – |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -64,500% | – | 13% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -73,512.3% | – | -2.6% | – |
| EPS Diluted | -0.37 | -0.32 | -0.008 | -0.36 |
| % Growth | -15.6% | -3,950.6% | 97.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |